Science Museum, Exhibition Rd, South Kensington, London SW7 2DD
Chair : Professor Sir Mark Walport
Honorary Distinguished Professor of Medicine, Imperial College London
The Galien Forum offers a day of dynamic presentations and spirited discussions with top scientists and industry researchers who offer perspectives on the most significant challenges in the global burden of disease and highlights the latest research and clinical pathways toward diagnosis, treatment, and cure.
10:40 AM – 11:40 AM
Prof. Sir Munir Pirmohamed,
David Weatherall Chair of Medicine, University of Liverpool
Luisa Freitas Dos Santos
Vice President – Global Clinical Supply Chain, GSK
CEO & MD of Wockhardt UK
Vice President Strategic Partners, IQVIA
Dr Bruce Warner
Deputy Chief Pharmaceutical Officer for England, NHS
Driving resilience in global medical product supply chains
Medical supply resilience is critical for the smooth running of global healthcare systems. Ensuring that essential medicines and products are launched and distributed to patients and healthcare providers in a timely and consistent manner is key for population health. The COVID-19 pandemic has highlighted the importance of supply resilience as disruptions in the global supply chain led to shortages of critical medicines at a time of global need. Driving supply resilience requires a multi-faceted approach across the supply ecosystem. In this panel, we will explore some of the current roadblocks and areas of risk that supply chains face and discuss how global medical product supply chains will need to adapt in the future.
12:00 AM – 1:00 PM
Dr Mel Walker, Biotech/Digital Health Adviser
Dr Murray Lumpkin
Lead for Global Regulatory Systems Initiatives, Bill & Melinda Gates Foundation
Head of Prequalification Unit, World Health Organization
Dr Samantha Roberts
Chief Executive Officer, National Institute for Health and Care Excellence
Dr Steffen Thirstrup
Chief Medical Officer, European Medicines Agency
Access to innovation: Exploring solutions to global challenges
Innovation in the healthcare sector has the ultimate goal of changing patients’ lives for the better. This is a global mission and yet there are huge variations in access for people living in different countries. Many innovations only end up reaching a small proportion of the patients who could benefit and this needs to change. However, the equitable delivery of health outcomes is a complex and multifaceted problem and the issues to be addressed vary significantly around the world. Some of the challenges include global regulatory processes and evolving payer controls, fragmented approaches to assessment and procurement, quality assurance and distribution, and affordability. This panel will explore these global issues along with initiatives and solutions that are being proposed or implemented to improve global health.
2:00 – 3:00 PM
Dr Stephanie Kuku, Health Technology Director, Senior Consultant, Hardian Health & Senior Adviser and Consultant, World Health Organization’s Department of Digital Health and Innovation
Pr The Lord Ara Darzi of Denham
Co-Director, Institute of Global Health Innovation, Imperial College London
Healthtech Partner, Octopus Ventures
Head of Decentralized Clinical Trials, Medable Inc.
Sarah Justine Kerruish
Chief Strategy Officer, Kheiron Medical Technologies
A discussion focused on the impact of AI / Digital on healthcare including where it has been deployed effectively to date, key priority areas and how to implement it in practice, in order to achieve desired healthcare outcomes. Discussion to be based around three key questions:
3:10 – 4:10 PM
Dr Jane Adam, NICE Technology Appraisal Committee and Consultant, St. George’s NHS Trust
Pr Lucy Chappell
Chief Scientific Adviser for Department of Health & Social Care (DHSC)
Dame Pr Helen Stokes-Lampard
Chair, Academy of Medical Royal Colleges
Chief Executive of Cambridge University Hospitals NHS Foundation Trust
What is the role of the NHS in public sector innovation?
The NHS is the largest single payer healthcare provider in the world, serving the needs of more than 50 million patients. As the number of people using NHS services increases and people continue to live longer, the NHS must create, foster and adopt innovations in order to service the needs of its users. Whilst public and private sector companies are utilising technological advancements to improve medicines and the ways care can be delivered, the NHS must manage how it can incorporate these innovations and also be a source for innovation itself. This panel will focus on the role of the NHS in public sector innovation. We will explore how it defines its needs and how it partners with academic institutions to drive improvements in the provision of healthcare.